Modality
ASO
MOA
MALT1i
Target
BCMA
Pathway
Notch
GBMMCCNB
Development Pipeline
Preclinical
~Jul 2012
→ ~Oct 2013
Phase 1
~Jan 2014
→ ~Apr 2015
Phase 2
~Jul 2015
→ ~Oct 2016
Phase 3
Jan 2017
→ Oct 2029
Phase 3Current
NCT03065073
1,604 pts·GBM
2017-01→2025-08·Completed
NCT07815340
108 pts·MCC
2023-08→2029-10·Active
1,712 total pts2 indications
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2025-08-227mo agoPh3 Readout· GBM
2029-10-193.6y awayPh3 Readout· MCC
Trial Timeline
2017Q2Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q4
P3
Complet…
P3
Active
Catalysts
Ph3 Readout
2025-08-22 · 7mo ago
GBM
Ph3 Readout
2029-10-19 · 3.6y away
MCC
ActiveCompleted|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03065073 | Phase 3 | GBM | Completed | 1604 | NT-proBNP |
| NCT07815340 | Phase 3 | MCC | Active | 108 | eGFR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-2735 | Johnson & Johnson | Phase 2/3 | Cl18.2 | |
| Riboinavolisib | Johnson & Johnson | Phase 2/3 | GLP-1R | |
| LLY-1956 | Eli Lilly | Phase 1/2 | BCMA | |
| RHH-974 | Roche | Preclinical | JAK1 | |
| NVS-3297 | Novartis | Preclinical | CDK2 | |
| ABB-8985 | AbbVie | Phase 2 | CD20 | |
| ABB-8696 | AbbVie | Phase 3 | BCMA | |
| AZN-4015 | AstraZeneca | Preclinical | BCMA | |
| REG-2328 | Regeneron | Phase 1 | BCMA | |
| Adagratapinarof | Vertex Pharma | Preclinical | BCMA |